Leukotriene modifiers--a new treatment option for asthma.
Wedekind
C A
CA
University of Rhode Island College of Pharmacy, Department of Pharmacy Practice, USA. wedekind@uri.edu
D000085:Acetates / Q000627:therapeutic use; D018927:Anti-Asthmatic Agents / Q000627:therapeutic use*; D003521:Cyclopropanes; D006801:Humans; D006918:Hydroxyurea / Q000031:analogs & derivatives / Q000627:therapeutic use; D007211:Indoles; D020024:Leukotriene Antagonists / Q000627:therapeutic use*; D048448:Phenylcarbamates; D011804:Quinolines / Q000627:therapeutic use; D013440:Sulfides; D013449:Sulfonamides; D014105:Tosyl Compounds / Q000627:therapeutic use; D016896:Treatment Outcome
D000085:Acetates; D018927:Anti-Asthmatic Agents; D003521:Cyclopropanes; D007211:Indoles; D020024:Leukotriene Antagonists; D048448:Phenylcarbamates; D011804:Quinolines; D013440:Sulfides; D013449:Sulfonamides; D014105:Tosyl Compounds; C093875:montelukast; C063449:zileuton; D006918:Hydroxyurea; C062735:zafirlukast